1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
136.25 USD   -4.97%
07:19aINSIDER SELL : Moderna
MT
06:48aPfizer says 3 COVID shots protect children under 5
AQ
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. administers 512.7 mln doses of COVID-19 vaccines - CDC

01/04/2022 | 04:35pm EDT

The United States has administered 512.7 million doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 614.4 million doses, the U.S. Centers for Disease Control and Prevention said.

Those figures are up from the 507.7 million vaccine doses the CDC said had gone into arms by Thursday. The CDC had not updated the figures since then due to holidays for New Year.

The agency said nearly 245 million people had received at least one dose while 206.6 million people are fully vaccinated as of 6:00 a.m. ET on Tuesday.

The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech , as well as Johnson & Johnson's one-shot vaccine.

About 71.6 million people have received a booster dose since Aug. 13, when the United States authorized a third dose of the vaccines for people with compromised immune systems who are likely to have weaker protection from the two-dose regimens.

(Reporting by Leroy Leo)


© Reuters 2022
All news about MODERNA, INC.
07:19aINSIDER SELL : Moderna
MT
06:48aPfizer says 3 COVID shots protect children under 5
AQ
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five year..
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
05/18Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
MT
05/18Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
MT
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/17TRANSCRIPT : Moderna, Inc. - Special Call
CI
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 5,01x
Yield 2022 -
Capitalization 54 195 M 54 195 M -
EV / Sales 2022 1,64x
EV / Sales 2023 3,33x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 136,25 $
Average target price 212,69 $
Spread / Average Target 56,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567
ALNYLAM PHARMACEUTICALS, INC.-22.00%15 980